摘要
肥胖是脂肪组织堆积引起的一种多基因调控的代谢性疾病。近年来,胃肠道-内分泌代谢间的相互作用关系备受关注,肠道菌群作为一个新的影响因素在肥胖的发生、发展中发挥重要作用。随着人类宏基因组计划的启动及高通量测序技术的发展,基于高通量测序技术为平台,将肠道菌群为靶点的精准体质量管理策略成为研究热点。目前肠道菌群干预减重的方法主要包括饮食干预、微生物制剂的使用、减重手术和粪菌移植等,然而肠道菌群的调节对减重效果的影响因方法的不同而异。
Obesity is a polygenic metabolic disease caused by accumulation of adipose tissue. Recently, the interaction between gastrointestinal tract and endocrine system has attracted much attention, and a~ growing body of evidence demonstrating that the disruption in the gut microbi0ta, is a central part to the pathogenesis of obesity. With the development of the human microbiome project and high-throughput sequencing technology, the study of gut microbiota has reached the level of genes. So that the precise weight management strategy based on high-throughput Sequencing technology as a platform with the gut microbiota as the target has become the focus of research. Currently, gut microbiota intervention includes diet intervention, bariatric surgery, microbiological agents and fecal bacteria transplantation, and the efficacy of gut microbiota modulation on obesity varies for different methods.
出处
《医学综述》
2017年第23期4577-4583,共7页
Medical Recapitulate
基金
国家自然科学基金(81570716)
关键词
高通量测序
肠道菌群
肥胖
饮食干预
减重手术
微生物制剂
High-throughput sequencing technologies
Gut microbiota
obesity
Diet intervention
Bariatric surgery
Microbiological agents
